ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Juvenile idiopathic arthritis"

  • Abstract Number: 0429 • ACR Convergence 2025

    Real-world experience of upadacitinib therapy in difficult-to-treat juvenile idiopathic arthritis: a case series of 24 patients

    Xuemei Tang1, Xiwen Luo2, Xiya Luo1, Mengwei Ding3, Xi Yang2, Dawei Liu2, Li Xu2, Zhiyong Zhang2, Yunfei An2 and Xiaodong Zhao1, 1Department of Rheumatology and Immunology, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Child Rare Diseases in Infection and Immunity, Chongqing, China, Chongqing, China (People's Republic), 2Department of Rheumatology & Immunology, Children’s Hospital of Chongqing Medical University, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, National Clinical Research Center for Child Health and Disorders (Chongqing), Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Child Infection and Immunity, Chongqing, China., Chongqing, China (People's Republic), 3Big Data Center for Children’s Medical Care, Children’s Hospital of Chongqing Medical University, Chongqing, China., Chongqing, China (People's Republic)

    Background/Purpose: Juvenile idiopathic arthritis (JIA) is a chronic rheumatic disease. Some patients experiencing active disease due to inadequate responses to conventional treatments. Studies have demonstrated…
  • Abstract Number: 0409 • ACR Convergence 2025

    Discordance Between Disease Activity and Patient-Reported Outcomes in Patients with Juvenile Idiopathic Arthritis

    Julia Harris1, Leslie Favier2, Emily Fox3, Jordan Jones2, Michael Holland3, Cara Hoffart2, Maria Ibarra3 and Ashley Cooper2, 1Children's Mercy Kansas City, Overland Park, KS, 2Children's Mercy Kansas City, Kansas City, MO, 3Children's Mercy Hospital, Kansas City, MO

    Background/Purpose: Outcome assessment is essential to optimize care for patients with juvenile idiopathic arthritis (JIA). Although disease activity and patient-reported outcomes (PROs) are different measures,…
  • Abstract Number: 0387 • ACR Convergence 2025

    Association Between Juvenile Arthritis and Physical Activity Levels in U.S. Children: A Cross-Sectional Study Using the 2016–2021 National Survey of Children’s Health

    William Soulsby1 and Carolina Tamashiro2, 1University of California, San Francisco, San Francisco, CA, 2UCSF, San Francisco, CA

    Background/Purpose: Juvenile arthritis (JA) is characterized by joint pain, stiffness, and decreased mobility, potentially affecting participation in physical activity (PA). Current guidelines from the CDC…
  • Abstract Number: 2138 • ACR Convergence 2025

    Factors driving therapeutic decision-making in Still’s Disease: When to Start and When to Stop? Data from the METAPHOR Project Worldwide Survey

    Francesco Baldo1, Greta Rogani2, Claudia Bracaglia3, Dirk Foell4, Marco Gattorno5, Marija Jelusic6, Jordi Anton7, Paul Brogan8, Scott Canna9, Randy Cron10, Fabrizio De Benedetti11, Alexei Grom12, Merav Heshin Bekenstein13, AnnaCarin Horne14, Raju Khubchandani15, Mao Mizuta16, Seza Özen17, Pierre Quartier Dit Maire18, Angelo Ravelli19, Masaki Shimizu20, Grant Schulert12, Christiaan Scott21, Rashmi Sinha22, Nicolino Ruperto23, Joost Swart24, Bruno Fautrel25, Sebastiaan Vastert2 and Francesca Minoia26, 1ASST-Pini-CTO, Milano, Milan, Italy, 2University Medical Center Utrecht, Utrecht, Utrecht, Netherlands, 3IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Rome, Italy, 4University Hospital Muenster, Muenster, Germany, 5IRCCS G. Gaslini, Genova, Genoa, Italy, 6University of Zagreb School of Medicine, University Hospital Centre Zagreb, Zagreb, Zagreb, Croatia, 7Hospital Sant Joan de Düu. Universitat de Barcelona, Esplugues de Llobregat (Barcelona), Spain, 8UCL Institute of Child Health and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, 9Children's Hospital of Philadelphia, Philadelphia, PA, 10University of Alabama at Birmingham, Birmingham, AL, 11Bambino Gesu Children's Hospital, Rome, Rome, Italy, 12Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 13Tel Aviv Medical Center Israel, Binyamina, Tel Aviv, Israel, 14Karolinska University Hospital, Sollentuna, Sweden, 15SRCC Childrens Hospital Mumbai, Mumbai, India, 16Hyogo Prefectural Kobe Children's Hospital, Kobe, Japan, Kobe, Japan, 17Hacettepe University Medical Faculty, Ankara, Turkey, 18Necker hospital, Paris Cedex 15, France, 19IRCCS Istituto Giannina Gaslini, Genoa, Italy, Genoa, Genoa, Italy, 20Tokyo Medical and Dental University, Bunkyo-ku, Kanazawa, Japan, 21Childrens Hospital of Eastern Ontario (CHEO), Ottawa, ON, Canada, 22Systemic JIA Foundation, Cincinnati, OH, 23Université Milano Bicocca and Fondazione IRCSS S. Gerardo dei Tintori, Monza, Monza and Brianza, Italy, 24Wilhelmina Children's Hospital / UMC Utrecht, Utrecht, Utrecht, Netherlands, 25Sorbonne Université - APHP, Department of Rheumatology, Hôpital Pitié-Salpêtrière, Inserm UMRS 1136-5, PARIS, France, Paris, France, 26Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Milan, Italy

    Background/Purpose: Despite continuous improvement in care and the recent update of international recommendations, relevant discrepancies in the diagnostic and treatment approach to Still’s disease (SD)…
  • Abstract Number: 1813 • ACR Convergence 2025

    Frequency of Tissue-Specific Activated CD8+ T Cells is Correlated To Disease Severity in Juvenile Idiopathic Arthritis

    Abigail Thielbar1, Tracy Ting2, Lexi Auld3, Kelly Rogers4, Megan Quinlan-Waters5, Sheila Angeles-Han4, Ekemini Ogbu2, Daniel Lovell2, Jennifer Huggins6, Grant Schulert2, Yuriy Baglaenko4 and Patricia Vega-Fernandez2, 1Cincinnati Children's Hospital, Cincinnati, 2Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 3Cincinnati Children's Hospital Medical Center, Division of Rheumatology, Cincinnati, OH, 4Cincinnati Children's Hospital, Cincinnati, OH, 5Cincinnati Children's Hospital Medical Center, CCHMC, 6Cincinnati Children's Medical Center, Cincinnati, OH

    Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is characterized by joint pain and inflammation. Persistent oligoarticular JIA(oligoJIA) is defined by the involvement of up to 4 joints…
  • Abstract Number: 0426 • ACR Convergence 2025

    Tofacitinib in Juvenile Idiopathic Arthritis: efficacy and safety in a clinical practice setting.

    Vicenç Torrente-Segarra1, Andrea Zacarias2, Cynthia Rojas3, Jordi Antón-López2, Judith Sanchez4 and Meritxell Salles Lizarzaburu5, 1Hospital Comarcal Alt Penedés Garraf, Vilafranca del Penedès, Spain, 2Pediatric Rheumatology Department, Hospital Sant Joan de Déu, Barcelona (Spain)., Barcelona, Spain, 3Rheumatology Department, Hospital Comarcal Alt Penedès Garraf, Vilafranca del Penedès (Spain)., Vilafranca del Penedes, Spain, 4Pediatric Rheumatology Department, Taulí Hospital Universitari-Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA), Sabadell (Spain)., Sabadell, Spain, 5Rheumatology Department, Althaia Xarxa Assistencial Universitària Manresa Manresa (Spain)., Manresa, Spain

    Background/Purpose: This study aims to evaluate the efficacy and safety of tofacitnib, a JAK inhibitor, in a multicentric cohort of patients with juvenile idiopathic arthritis…
  • Abstract Number: 0407 • ACR Convergence 2025

    The SOS project: to Switch Or to Swap After Adalimumab failure for the management of childhood non-infectious uveitis in an international cohort

    Ilaria Maccora1, Margaret Chang2, Sheila Angeles-Han3, Andrea Taddio4, Lampros Fotis5, Cinzia de Libero6, Madison Mangin7, Alexandra Duell8, Marco Gabrielli9, Kyveli Chiotopoulou5, Lillian Sutton10, Virginia Miraldi Utz8 and Gabriele Simonini11, 1Rheumatology Unit, ERN ReCoNNET Center, Meyer Children's Hospital IRCCS, Florence, Italy, Firenze, Florence, Italy, 2Boston Children's Hospital, Boston, MA, 3Cincinnati Children's Hospital, Cincinnati, OH, 4Insitute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste, Italy, 5Division of Pediatric Rheumatology, Department of Pediatrics, ATTIKON General Hospital, National and Kapodistrian University of Athens, Greece, Athene, Greece, 6Ophthalmology Unit, Meyer Children's Hospital IRCCS, Florence, Italy, Florence, Italy, 7Boston Children's Hospital, St Simons Island, GA, 8Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 9University of Trieste, Trieste, Italy, Trieste, Italy, 10Division of Immunology, Boston Children’s Hospital, Boston, MA, USA, Boston, 11Rheumatology Unit, ERN-ReCONNET center, Meyer Children's Hospital IRCCS, Firenze, Firenze, Italy

    Background/Purpose: Childhood chronic non-infectious uveitis (cNIU) is a sight-threatening condition that can lead to blindness if not appropriately treated. cNIU is typically associated with Juvenile…
  • Abstract Number: 0312 • ACR Convergence 2025

    Efficacy and Safety of Tocilizumab in Children with Juvenile Idiopathic Arthritis: A Systematic Review and Meta-Analysis

    Kainat Jahangir1, Meer Murtaza2, Rida Ul Jannat3, Muhammad Arham4, Najam Gohar5, Faseeh Haider6, Rohma Ahmed7, FNU Raja8, Rabie Habib9, Mahnoor Umar10, Hira Saleem11, Faizan Ahmed12, Tehmasp Mirza13, Momina Siddiqui14, Muhammad Umer15, Haziq Ahmed16, Maryam Anwar17, Rehab Bint e Tahir18, Yusra Junaid19 and Ramsha Ali20, 1Dow Medical College, Karachi, Pakistan, 2Liaquat University of Medical and Health Sciences, Jamshoro, Pakistan, 3Wake Forest University, Winston Salem North Carolina, Winston-Salem, NC, 4Sheikh Zayed Medical College, Lahore, Pakistan, 5Ameer Ud Din Medical College, Sialkot, Pakistan, 6Allama Iqbal Medical college, Lahore, Punjab, Pakistan, 7Fatima Jinnah Medical University, Lahore, Pakistan, 8Federal Medical and Dental College, Islamabad, Pakistan, 9Baylor College of Medicine, Texas, Pakistan, 10Nassau University Medical Center, New York, 11Houston Methodist Hospital, Texas, 12Corewell health, dearborn, MI, 13Shalamar Medical and Dental College, Lahore, Pakistan, 14Rawalpindi Medical Univeristy, Rawalpindi, Punjab, Pakistan, 15King Edward Medical College, Lahore, Pakistan, 16Sheikh Khalifa bin zayed Alnahyan Medical College, Lahore, Punjab, Pakistan, 17Baqai Medical University, Karachi, Pakistan, 18-, lahore, 19Dow University of health and sciences, karachi, Pakistan, 20Peoples University of Medical and Health Sciences SBA, NawabShah, Pakistan

    Background/Purpose: Juvenile idiopathic arthritis (JIA) encompasses various chronic inflammatory conditions in children that lead to joint discomfort and potential disability. Tocilizumab, an antibody targeting interleukin-6,…
  • Abstract Number: 2137 • ACR Convergence 2025

    Therapeutic Strategies in Newly Diagnosed Still’s Disease: Real-Life Clinicians’ Choices from the METAPHOR Project Worldwide Survey

    Francesco Baldo1, Greta Rogani2, Claudia Bracaglia3, Dirk Foell4, Marco Gattorno5, Jordi anton6, Paul Brogan7, Scott Canna8, randy Cron9, Alexiei GROM10, Merav Heshin Bekenstein11, Raju Khubchandani12, Seza Özen13, Pierre Quartier14, Angelo Ravelli15, Grant Schulert16, Mao Mizuta17, Joost Swart18, Rashmi Sinha19, AnnaCarin Horne20, Fabrizio De Benedetti21, Christiaan Scott22, Marija Jelusic23, Masaki Shimizu24, Bruno Fautrel25, Nicolino Ruperto26, Sebastiaan Vastert2 and Francesca Minoia27, 1ASST-Pini-CTO, Milano, Milan, Italy, 2University Medical Center Utrecht, Utrecht, Utrecht, Netherlands, 3IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Rome, Italy, 4Universisty Hospital of Muenster, Muenster, 5IRCCS G. Gaslini, Genova, Genoa, Italy, 6Hospital Sant Joan de Düu. Universitat de Barcelona, Barcelona, Spain, 7UCL Institute of Child Health and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, 8Children's Hospital of Philadelphia, Philadelphia, PA, 9University of Alabama at Birmingham, Birmingham, AL, 10Cincinnati Children’s Hospital Medical Center, Division of Rheumatology, Cincinnati, OH, 11Tel Aviv Medical Center Israel, Binyamina, Tel Aviv, Israel, 12Jaslok Hospital and Research Center, Mumbai, India, 13Hacettepe University Medical Faculty, Ankara, Turkey, 14Hôpital Necker-Enfants Malades, Paris, France, 15IRCCS Istituto Giannina Gaslini, Genoa, Italy, Genoa, Genoa, Italy, 16Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 17Hyogo Prefectural Kobe Children's Hospital, Kobe, Japan, Kobe, Japan, 18Wilhelmina Children's Hospital / UMC Utrecht, Utrecht, Utrecht, Netherlands, 19Systemic JIA Foundation, Cincinnati, OH, 20Karolinska University Hospital, Sollentuna, Sweden, 21Bambino Gesu Children's Hospital, Rome, Rome, Italy, 22Childrens Hospital of Eastern Ontario (CHEO), Ottawa, ON, Canada, 23University of Zagreb School of Medicine, University Hospital Centre Zagreb, Zagreb, Zagreb, Croatia, 24Tokyo Medical and Dental University, Bunkyo-ku, Kanazawa, Japan, 25Sorbonne Université - APHP, Department of Rheumatology, Hôpital Pitié-Salpêtrière, Inserm UMRS 1136-5, PARIS, France, Paris, France, 26Université Milano Bicocca and Fondazione IRCSS S. Gerardo dei Tintori, Monza, Monza and Brianza, Italy, 27Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Milan, Italy

    Background/Purpose: Despite continuous advances in care and the recent publication of updated international recommendations, relevant discrepancies in the management of Still’s disease (SD) may still…
  • Abstract Number: 1812 • ACR Convergence 2025

    Inflammasome and UPR activation in monocytes of HLA B27 positive children with Enthesitis related arthritis category of JIA

    Shivika Guleria1 and Amita Aggarwal2, 1SGPGIMS, Lucknow, Lucknow, Uttar Pradesh, India, 2Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India

    Background/Purpose: Enthesitis related arthritis (ERA) is a chronic immune-inflammatory disease with unknown etiology. HLA-B27 is the strongest risk factor predisposing to ERA like Spondyloarthritis (SpA).…
  • Abstract Number: 0427 • ACR Convergence 2025

    Maternal Smoking During Pregnancy and Risk of Juvenile Idiopathic Arthritis (JIA): Triangulating Evidence from Polygenic Risk Scores and Meta-Analysis in Scandinavian Birth Cohorts

    Vilde Øverlien Dåstøl1, Kristine Løkås Haftorn2, Maria Christine Magnus3, Sigrid Hestetun4, Siri Eldevik Håberg5, Lisa Rider6, Karen H. Costenbader7, Ida Henriette Caspersen8, Sjurdur Frodi Olsen9, Ketil Størdal10 and Helga Sanner1, 1Oslo University Hospital, Oslo, Norway, 2Oslo University Hospital, Department of Rheumatology, Oslo, Norway, 3Norwegian Institute of Public Health, Centre for Fertility and Health, Oslo, Norway, 4Oslo University Hospital, Department of Rheumatology/University of Oslo, Oslo, Norway, 5Norwegian Institute of Public Health, Centre for Fertility and Health/University of Bergen, Oslo, Norway, 6National Institute of Environmental Health Sciences/National Institutes of Health, Environmental Autoimmunity Group, Bethesda, MD, 7Harvard Medical School and Brigham and Women's Hospital, Boston, MA, 8Norwegian Institute of Public Health, Centre for Fertility and Health/Oslo University Hospital, Oslo, Norway, 9Statens Serum Institut,Biobank, congenital disorders, and vaccines preparedness/Harvard T.H. Chan School of Public Health, Copenhagen, Denmark, 10Oslo University Hospital, Department of Pediatric and Adolescent Medicine/University of Oslo, Oslo, Norway

    Background/Purpose: Maternal smoking during pregnancy has been associated with a seemingly lower risk of juvenile idiopathic arthritis (JIA) in the child (1), contrasting with smoking’s…
  • Abstract Number: 0406 • ACR Convergence 2025

    Comparing biomarkers associated with uveitis in tear fluid and serum samples of children with Juvenile Idiopathic Arthritis

    Ilaria Maccora1, Mariia Pavlenko2, Mekibib Altaye3, Hermine Brunner4, Margaret Chang5, Ashley Cooper6, Stefanie Davidson7, Alexandra Duell4, Bharti Gangwani5, Aimee Hersh8, Gary Holland9, Carl Langefeld10, Melissa Lerman11, Mindy Lo5, Virginia Miraldi Utz4, Sampath Prahalad12, Grant Schulert4, Megan Quinlan-Waters13, Erin Stahl6, Edmund Tsui9 and Sheila Angeles-Han14, 1Rheumatology Unit, ERN ReCoNNET Center, Meyer Children's Hospital IRCCS, Florence, Italy, Firenze, Florence, Italy, 2Rheumatology Division, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA, Cincinnati, OH, 3Cincinnati Children's Hospital, Cincinnati, 4Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 5Boston Children's Hospital, Boston, MA, 6Children's Mercy Kansas City, Kansas City, MO, 7Department of Ophthalmology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, Philadelphia, PA, 8University of Utah, Salt Lake City, UT, 9UCLA Jules Stein Eye Institute and the Department of Ophthalmology, UCLA David Geffen School of Medicine, Los Angeles, 10Wake Forest University School of Medicine, Winston Salem, NC, 11Children's Hospital of Philadelphia, Philadelphia, PA, 12Emory + Children's Pediatric Institute, Atlanta, GA, 13Cincinnati Children's Hospital Medical Center, CCHMC, 14Cincinnati Children's Hospital, Cincinnati, OH

    Background/Purpose: Chronic anterior uveitis (CAU) develops in 15-20% of juvenile idiopathic arthritis (JIA) cases. Early detection may prevent vision loss. However, known clinical risk factors…
  • Abstract Number: 0028 • ACR Convergence 2025

    Computational and Laboratory Identification of Risk-Driving Alleles on Juvenile Idiopathic Arthritis (JIA)-Associated Haplotypes

    Adam He1, Hannah Ainsworth2, Kaiyu Jiang3, Ekaterina Khtovatkova2, Yanmin Chen3, Carl Langefeld4, Charles G Danko1 and James N. Jarvis5, 1Cornell University Baker School of Veterinary Medicine, Ithaca, NY, 2Wake Forest University, Winston-Salem, NC, 3University of Washington School of Medicine, Seattle, WA, 4Wake Forest University School of Medicine, Winston Salem, NC, 5University of Washington Center for Indigenous Health, Seattle, WA

    Background/Purpose: Multiple genomic regions are known to confer risk for JIA. However, identifying the SNPs that exert the biological effects that confer risk, and therefore…
  • Abstract Number: 2134 • ACR Convergence 2025

    Krebs von den Lungen-6 (KL-6) as a Potential Diagnostic Biomarker of Lung Disease in Pediatric Systemic Juvenile Idiopathic Arthritis: Preliminary Findings from a Multisite US Cohort

    Eileen Rife1, Lexi Auld2, Guihua Zhai3, Esraa Eloseily4, Grant Schulert5 and Yukiko Kimura6, 1University of Alabama at Birmingham, birmingham, AL, 2Cincinnati Children's Hospital Medical Center, Division of Rheumatology, Cincinnati, OH, 3UAB, Birmingham, 4UT Southwestern Children's Medical Center, Dallas, TX, 5Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 6Hackensack Meridian School of Medicine, New York, NY

    Background/Purpose: Children with Systemic Juvenile Idiopathic Arthritis (SJIA) who develop lung disease (LD) are at significantly increased risk of serious complications and even death. Early…
  • Abstract Number: 1811 • ACR Convergence 2025

    Pharmacogenomic analysis of prediction of IL-1 Inhibitor treatment response in the CARRA First-line Options for Systemic Juvenile Idiopathic Arthritis Treatment (FROST) Study

    Mariana Correia Marques1, Michael Matt2, Sophia Chou3, Peter Burbelo4, Zuoming Deng5, George Tomlinson6, Yukiko Kimura7, Grant Schulert2 and Michael Ombrello8, 1Translational Genetics and Genomics Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 2Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 3National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH, Rockville, MD, 4Adeno-Associated Virus Biology Section, National Institute of Dental and Craniofacial Research (NIDCR), Bethesda, 5Biodata Mining and Discovery Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 6University of Toronto, Toronto, ON, Canada, 7Hackensack Meridian School of Medicine, New York, NY, 8National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), North Bethesda, MD

    Background/Purpose: Interleukin (IL)-1 inhibitors are now regarded as the first line treatment option for systemic juvenile idiopathic arthritis (sJIA), however in up to half of…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 25
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology